Product Reports Resources Pricing Login Book a demo

Lyell Immunopharma

Biotech & Life Sciences · San Francisco, United States · Founded 2018 · IPO 2021

Operator of a biotechnology company that develops cellular therapies to cure cancer

Valuation $103M
Revenue $36K
Power Law Unicorn$1–10B valuation tier

Investors

6 investors on Lyell Immunopharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
ARCH Venture Partners
Arrive Roc Nation
Bill & Melinda Gates Foundation
8VC
Sahsen Ventures
Series B+ 1 investor entered at this stage
University of Washington

Global footprint

Where Lyell Immunopharma has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States99.9%
🇯🇵 Japan0.6%
2 countries shown
Web traffic by country
7.4K monthly visits
across markets
🇺🇸 United States77%
🇮🇳 India13.5%
🇨🇦 Canada9.5%
Top 3 markets shown

Talent graph

The shape of Lyell Immunopharma's talent

Dealroom maps Lyell Immunopharma's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

16 standout operatorsDealroom-flagged across the org
1 AI specialistpinpointed by name
233 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Lyell Immunopharma's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$8M patent portfolio · 35 active families

Estimated portfolio value
$8M
7.5% of market cap · 917.9× smaller than top peer Janssen Vaccines ($7.1B)
35 active patent families
Where Lyell Immunopharma innovates Molecular biologyAnti antibodyAntiendomysial antibodiesAntigenAntigen Binding Fragment

Where Lyell Immunopharma concentrates vs peers

Each axis is a top-10 topic across Lyell Immunopharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Lyell Immunopharma's 6 investments and acquisitions.

Every disclosed deal where Lyell Immunopharma appeared as a backer or acquirer, 2020–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across Lyell Immunopharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Lyell Immunopharma deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Lyell Immunopharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        What the market is saying about Lyell Immunopharma

        An AI-synthesized read of the highest-engagement posts about Lyell Immunopharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Lyell Immunopharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles